BP2202

BP2202 is an iPS cell-derived CAR-iNKT cell therapy (allogeneic) from BrightPath Biotherapeutics. An off-the-shelf allogeneic CAR therapy using NKT cells regenerated from iPS cells, targeting BCMA on myeloma cells. Its furthest stage is phase 1, for relapsed or refractory multiple myeloma. ClinicalTrials.gov registers it in one study linked below. US phase 1 NCT07667868 not yet recruiting (registry, 3 Nov 2026). FDA orphan drug designation July 2025 per company page. Whether it works in people has not been established unless a trial below reports it.